Active clinical trials combining radiation with TGF-β blockade or GM-CSF

NCT NumberPhasesTitleConditionInterventionRT DetailsEnrollmentSponsor/Collaborators
Anti-TGF- β
NCT02538471Phase 2LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast CancerMetastatic Breast CancerLY2157299RT, 7.5 Gy × 3 fx28Weill Medical College of Cornell University|University of California, Los Angeles
NCT02581787Phase 1|Phase 2SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung CancerStage IA-B NSCLCFresolimumabSBRT, 4 fx60Maximilian Diehn|National Cancer Institute (NCI)|Stanford University
GM-CSF
NCT02623595Phase 2A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyNon-small cell lung cancerGM-CSFSBRT, 10 Gy × 5 fx60Wuhan University|Tongji Hospital|Hubei Cancer Hospital
NCT02663440Phase 2Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma MultiformeGlioblastomaGM-CSF, TemozolomideHypofx IMRT41Zhejiang Cancer Hospital
NCT02677155Phase 2Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular LymphomaFollicular LymphomaGM-CSF, Pembrolizumab, Rituximab, autologous dendritic cells8 Gy × 120Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp.
NCT02648282Phase 2Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic CancerPancreatic CancerGVAX, Cyclophosphamide, PembrolizumabSBRT, 6.6 Gy × 5 fx54Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.

Abbreviations: GM-CSF granulocyte macrophage colony stimulating factor, Hypofx hypofractionated, IMRT intensity modulated radiation therapy, NSCLC non-small cell lung cancer, SBRT stereotactic body radiation therapy